Form 8-K - Current report:
SEC Accession No. 0001493152-22-024982
Filing Date
2022-09-02
Accepted
2022-09-02 16:32:21
Documents
13
Period of Report
2022-08-30
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40817
  Complete submission text file 0001493152-22-024982.txt   254935

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ptix-20220830.xsd EX-101.SCH 4001
3 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ptix-20220830_def.xml EX-101.DEF 26655
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ptix-20220830_lab.xml EX-101.LAB 36749
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ptix-20220830_pre.xml EX-101.PRE 25279
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5416
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 221225605
SIC: 7389 Services-Business Services, NEC